This company listing is no longer active
Sirnaomics Toekomstige groei
Future criteriumcontroles 2/6
Sirnaomics is forecast to grow revenue at 63.5% per annum.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Biotechs winstgroei | 41.8% |
| Inkomstengroei | 63.5% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 03 Jun 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 161 | N/A | -138 | N/A | 1 |
| 12/31/2025 | 70 | N/A | -159 | N/A | 1 |
| 12/31/2024 | 2 | -124 | -120 | -126 | 1 |
| 6/30/2024 | 1 | -82 | -49 | -47 | N/A |
| 3/31/2024 | 1 | -80 | -61 | -59 | N/A |
| 12/31/2023 | 0 | -79 | -72 | -70 | N/A |
| 9/30/2023 | 0 | -82 | -82 | -76 | N/A |
| 6/30/2023 | 0 | -84 | -93 | -82 | N/A |
| 3/31/2023 | 0 | -86 | -100 | -85 | N/A |
| 12/31/2022 | 1 | -88 | -108 | -89 | N/A |
| 9/30/2022 | 1 | -230 | -103 | -87 | N/A |
| 6/30/2022 | 1 | -223 | -96 | -83 | N/A |
| 3/31/2022 | 0 | -218 | -80 | -70 | N/A |
| 12/31/2021 | 0 | -213 | -63 | -57 | N/A |
| 9/30/2021 | 0 | -60 | -49 | -44 | N/A |
| 12/31/2020 | N/A | -44 | -21 | -19 | N/A |
| 12/31/2019 | 0 | -16 | -16 | -14 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if 2257's forecast earnings growth is above the savings rate (2.3%).
Winst versus markt: Insufficient data to determine if 2257's earnings are forecast to grow faster than the Hong Kong market
Hoge groeiwinsten: Insufficient data to determine if 2257's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: 2257's revenue (63.5% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
Hoge groei-inkomsten: 2257's revenue (63.5% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 2257's Return on Equity is forecast to be high in 3 years time